Want to see NMRA full AI Analyst Report?
NMRA Stock Chart & Stats
$1.49
$0.18(12.08%)
At close: 4:00 PM EDT
$1.49
$0.18(12.08%)
Day’s Range― - ―
52-Week Range$0.83 - $3.65
Previous CloseN/A
Volume485.06K
Average Volume (3M)490.26K
Market Cap
$305.72M
Enterprise Value$257.05
Total Cash (Recent Filing)$147.07M
Total Debt (Recent Filing)$410.00K
Price to Earnings (P/E)―
Beta2.29
Next Earnings
Aug 12, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.33
Shares Outstanding185,284,240
10 Day Avg. Volume506,087
30 Day Avg. Volume490,256
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.82
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.33Price Target Upside325.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.91
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageNeumora's very low total debt and minimal debt-to-equity reduce solvency and interest-rate risk versus peers. For a pre-commercial biotech this preserves strategic optionality to fund multi-year R&D via equity or partnerships rather than onerous debt, supporting execution flexibility.
NMRA-215 Toxicology Supports INDRobust repeat toxicology and supporting 28-day/13-week dog studies materially de-risk NMRA-215 on the preclinical safety axis. Combined with strong preclinical efficacy and planned IND timing, this provides a durable pathway to expand into obesity/cardiometabolic indications and diversify value drivers.
Restructuring Extends RunwayA ~35% headcount reduction plus loan amendments and a minimum-liquidity covenant tied to milestones materially lower near-term burn (~$10M annualized savings) and extend runway. This structural cost base change reduces immediate financing pressure while the company advances remaining programs.
Bears Say
No Revenue; Large LossesNeumora lacks product revenues and reports multi-year operating losses, meaning ongoing operations depend on external funding or collaborations. This structural lack of internal cash generation raises dilution risk and constrains long-term planning until clinical success or partnerships are secured.
Loss Of Late-stage AssetDiscontinuing navacaprant after Phase 3 failures eliminates the company's only late-stage program, concentrating value creation on earlier-stage assets. This increases binary clinical risk and lengthens timelines to potential value realization, pressuring remaining programs to deliver major milestones.
Heavy Cash Burn / Negative FCFPersistent, worsening negative operating and free cash flow indicates sustained high funding needs. Over months this elevates probability of equity raises or dilutive partnerships, which can reduce shareholder value and force reprioritization of R&D programs away from long-term projects.
Neumora Therapeutics, Inc. News
NMRA FAQ
What was Neumora Therapeutics, Inc.’s price range in the past 12 months?
Neumora Therapeutics, Inc. lowest stock price was $0.83 and its highest was $3.65 in the past 12 months.
What is Neumora Therapeutics, Inc.’s market cap?
Neumora Therapeutics, Inc.’s market cap is $305.72M.
When is Neumora Therapeutics, Inc.’s upcoming earnings report date?
Neumora Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 12 days.
How were Neumora Therapeutics, Inc.’s earnings last quarter?
Neumora Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.316 by $0.016.
Is Neumora Therapeutics, Inc. overvalued?
According to Wall Street analysts Neumora Therapeutics, Inc.’s price is currently Undervalued.
Does Neumora Therapeutics, Inc. pay dividends?
Neumora Therapeutics, Inc. does not currently pay dividends.
What is Neumora Therapeutics, Inc.’s EPS estimate?
Neumora Therapeutics, Inc.’s EPS estimate is -0.24.
How many shares outstanding does Neumora Therapeutics, Inc. have?
Neumora Therapeutics, Inc. has 185,284,240 shares outstanding.
What happened to Neumora Therapeutics, Inc.’s price movement after its last earnings report?
Neumora Therapeutics, Inc. reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.316. Following the earnings report the stock price went down -16.738%.
Which hedge fund is a major shareholder of Neumora Therapeutics, Inc.?
Currently, no hedge funds are holding shares in NMRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neumora Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.33 (325.06% Upside)
$6.33 (325.06% Upside)
Hedge Fund Trend
Increased
By 4.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-89.79%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-40.07%
Trailing 12-Months
Company Description
Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
NMRA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong scientific and clinical momentum across several programs with multiple near-term catalysts (NMRA-511, navacaprant KOASTAL-2/3, NMRA-898) and compelling preclinical/early clinical data (notably NMRA-511 effect sizes and NMRA-215 DIO results). However, a non-dose-dependent adverse signal in a 13-week rat tox study for NMRA-215, associated study conduct issues and the need to repeat toxicology introduce timeline, regulatory and cost risk for that program. Financial runway of $182.5M into Q3 2027 is adequate for the near term but will require careful capital allocation as multiple programs advance. Overall, positives on pipeline progress and enrollments outweigh the headwinds from the NMRA-215 tox delay and finite cash runway, but risks remain tied to upcoming pivotal readouts.View all NMRA earnings summariesNMRA Stock 12 Month Forecast
Average Price Target
$6.33
▲(325.06% Upside)
Technical Analysis
Abeona Therapeutics
―
AC Immune SA
―
Allogene Therapeutics
―
―
Aardvark Therapeutics, Inc.
―
Ownership Overview
59.25% Insiders
3.26% Mutual Funds
3.05% Other Institutional Investors
28.19% Public Companies and
Individual Investors